The above results suggest that clinicians should monitor serum HA, CIV, CHI3L1 levels in OSA patients and judge the liver damage by combining the levels of AHI and LaSO2, to select the appropriate treatment plan as soon as possible. This evidence concerns the gene CHI3L1 and obstructive sleep apnea syndrome.